Table 1.
Biopsy characteristics from the 5 PBCG cohorts.
| SABOR | Cleveland Clinic | ProtecT | Tyrol | Durham VA | |
|---|---|---|---|---|---|
| Number of patients | 722 | 2603 | 7260 | 3628 | 1674 |
| Number of biopsies | 900 | 3257 | 7260 | 4788 | 2195 |
| Years of observation | 2001–2010 | 2000–2008 | 2001–2008 | 1995–2007 | 1994–2009 |
| Age median (range) | 63.9 (36, 89) | 64.0 (50, 75) | 62.6 (50, 72) | 62.0 (50, 75) | 63.9 (50, 75) |
| PSA median (range) | 3.3 (0.1, 49.8) | 5.7 (0.2, 49.9) | 4.3 (3.0, 49.7) | 4.0 (0.2, 49.6) | 5.0 (0.1, 49.5) |
| < 3 ng/ml | 385 (43%) | 337 (10%) | 0 (0%) | 1519 (32%) | 288 (13%) |
| ≥ 3 ng/ml | 515 (57%) | 2920 (90%) | 7260 (100%) | 3269 (68%) | 1907 (87%) |
| DRE result | |||||
| Normal | 603 (67%) | 3057 (94%) | 0 (0%) | 4425 (92%) | 876 (40%) |
| Abnormal | 234 (26%) | 200 (6%) | 0 (0%) | 363 (8%) | 251 (11%) |
| Unknown | 63 (7%) | 0 (0%) | 7260 (100%) | 0 (0%) | 1068 (49%) |
| Family history | |||||
| No | 246 (27%) | 1679 (52%) | 5692 (78%) | 0 (0%) | 0 (0%) |
| Yes | 295 (33%) | 371 (11%) | 453 (6%) | 0 (0%) | 0 (0%) |
| Unknown | 359 (40%) | 1207 (37%) | 1115 (15%) | 4788 (100%) | 2195 (100%) |
| African origin | |||||
| No | 796 (88%) | 2799 (86%) | 6878 (95%) | 0 (0%) | 1114 (51%) |
| Yes | 104 (12%) | 412 (13%) | 31 (0%) | 0 (0%) | 969 (44%) |
| Unknown | 0 (0%) | 46 (1%) | 351 (5%) | 4788 (100%) | 112 (5%) |
| Prior biopsy | |||||
| Yes | 306 (34%) | 1089 (33%) | 0 (0%) | 1434 (30%) | 550 (25%) |
| No | 594 (66%) | 2168 (67%) | 7260 (100%) | 3354 (70%) | 1645 (75%) |
| Cancer | 287 (32%) | 1265 (39%) | 2507 (35%) | 1320 (28%) | 973 (44%) |
| Biopsy Gleason grade | |||||
| < 7 | 193 (67%) | 668 (53%) | 1695 (68%) | 860 (65%) | 529 (54%) |
| ≥ 7 | 92 (32%) | 597 (47%) | 812 (32%) | 421 (32%) | 434 (45%) |
| Unknown | 2 (1%) | 0 (0%) | 0 (0%) | 39 (3%) | 10 (1%) |